Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo

Key Points

• The research aims to clarify the interactions of ribociclib with OATP1B and its implications for drug co-administration.
• Conducted in vivo analysis of ribociclib's effects on OATP1B
• Evaluated ribociclib as a substrate and inhibitor of OATP1B
• Examined potential clinically significant interactions
• Ribociclib does not act as a substrate for OATP1B
• Ribociclib does not inhibit OATP1B-mediated uptake
• No anticipated significant drug interactions with OATP1B

Abstract